Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):...

Keywords

MedicinePembrolizumabInternal medicineLung cancerOncologyChemotherapyPerformance statusProgression-free survivalCancerImmunotherapy

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

Rina Hui , Leena Gandhi , Enric Carcereny +17 more

9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This app...

2016 Journal of Clinical Oncology 58 citations

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Publication Info

Year: 2019
Type: article
Volume: 393
Issue: 10183
Pages: 1819-1830
Citations: 3175
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3175

OpenAlex

Cite This

APA Style

                            
                                
                                    Tony Mok, 
                                
                                    Yi‐Long Wu, 
                                
                                    Iveta Kudaba
                                
                                et al.
                            
                            (2019). 
                            Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. 
                            The Lancet
                            , 393
                            (10183)
                            , 1819-1830.
                            https://doi.org/10.1016/s0140-6736(18)32409-7
                        

Identifiers

DOI: 10.1016/s0140-6736(18)32409-7